These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 15882516)

  • 41. Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH).
    Yamagishi S; Nakamura K; Inoue H
    Med Hypotheses; 2005; 65(2):377-9. PubMed ID: 15922116
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Acetyl-L-carnitine and lipoic acid improve mitochondrial abnormalities and serum levels of liver enzymes in a mouse model of nonalcoholic fatty liver disease.
    Kathirvel E; Morgan K; French SW; Morgan TR
    Nutr Res; 2013 Nov; 33(11):932-41. PubMed ID: 24176233
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease.
    Scorletti E; Byrne CD
    Annu Rev Nutr; 2013; 33():231-48. PubMed ID: 23862644
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet.
    Matsuzawa N; Takamura T; Kurita S; Misu H; Ota T; Ando H; Yokoyama M; Honda M; Zen Y; Nakanuma Y; Miyamoto K; Kaneko S
    Hepatology; 2007 Nov; 46(5):1392-403. PubMed ID: 17929294
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oxidative stress, KLF6 and transforming growth factor-beta up-regulation differentiate non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats.
    Stärkel P; Sempoux C; Leclercq I; Herin M; Deby C; Desager JP; Horsmans Y
    J Hepatol; 2003 Oct; 39(4):538-46. PubMed ID: 12971963
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lavatera critica, a green leafy vegetable, controls high fat diet induced hepatic lipid accumulation and oxidative stress through the regulation of lipogenesis and lipolysis genes.
    Veeramani C; Alsaif MA; Al-Numair KS
    Biomed Pharmacother; 2017 Dec; 96():1349-1357. PubMed ID: 29174039
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver.
    Begriche K; Massart J; Robin MA; Borgne-Sanchez A; Fromenty B
    J Hepatol; 2011 Apr; 54(4):773-94. PubMed ID: 21145849
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mechanisms of disease: adipocytokines and visceral adipose tissue--emerging role in nonalcoholic fatty liver disease.
    Schäffler A; Schölmerich J; Büchler C
    Nat Clin Pract Gastroenterol Hepatol; 2005 Jun; 2(6):273-80. PubMed ID: 16265231
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mesenteric Fat Lipolysis Mediates Obesity-Associated Hepatic Steatosis and Insulin Resistance.
    Wueest S; Item F; Lucchini FC; Challa TD; Müller W; Blüher M; Konrad D
    Diabetes; 2016 Jan; 65(1):140-8. PubMed ID: 26384383
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mechanisms of Disease: pathogenesis of nonalcoholic fatty liver disease.
    Sanyal AJ
    Nat Clin Pract Gastroenterol Hepatol; 2005 Jan; 2(1):46-53. PubMed ID: 16265100
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Role of oxidative stress in non-alcoholic steatohepatitis].
    Mitsuyoshi H; Itoh Y; Okanoue T
    Nihon Rinsho; 2006 Jun; 64(6):1077-82. PubMed ID: 16768112
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease.
    Nomura K; Yamanouchi T
    J Nutr Biochem; 2012 Mar; 23(3):203-8. PubMed ID: 22129639
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rutin exhibits hepatoprotective effects in a mouse model of non-alcoholic fatty liver disease by reducing hepatic lipid levels and mitigating lipid-induced oxidative injuries.
    Liu Q; Pan R; Ding L; Zhang F; Hu L; Ding B; Zhu L; Xia Y; Dou X
    Int Immunopharmacol; 2017 Aug; 49():132-141. PubMed ID: 28577437
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Non-alcoholic fatty liver disease pathogenesis: the present and the future.
    Petta S; Muratore C; Craxì A
    Dig Liver Dis; 2009 Sep; 41(9):615-25. PubMed ID: 19223251
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dietary modification dampens liver inflammation and fibrosis in obesity-related fatty liver disease.
    Larter CZ; Yeh MM; Haigh WG; Van Rooyen DM; Brooling J; Heydet D; Nolan CJ; Teoh NC; Farrell GC
    Obesity (Silver Spring); 2013 Jun; 21(6):1189-99. PubMed ID: 23666886
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Non-alcoholic fatty liver disease. From insulin resistance to mitochondrial dysfunction.
    Solís Herruzo JA; García Ruiz I; Pérez Carreras M; Muñoz Yagüe MT
    Rev Esp Enferm Dig; 2006 Nov; 98(11):844-74. PubMed ID: 17198477
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mice lacking liver-specific β-catenin develop steatohepatitis and fibrosis after iron overload.
    Preziosi ME; Singh S; Valore EV; Jung G; Popovic B; Poddar M; Nagarajan S; Ganz T; Monga SP
    J Hepatol; 2017 Aug; 67(2):360-369. PubMed ID: 28341391
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diabetes of the liver: the link between nonalcoholic fatty liver disease and HFCS-55.
    Collison KS; Saleh SM; Bakheet RH; Al-Rabiah RK; Inglis AL; Makhoul NJ; Maqbool ZM; Zaidi MZ; Al-Johi MA; Al-Mohanna FA
    Obesity (Silver Spring); 2009 Nov; 17(11):2003-13. PubMed ID: 19282820
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of lipid metabolism in the pathogenesis of alcoholic and nonalcoholic hepatic steatosis.
    Sozio MS; Liangpunsakul S; Crabb D
    Semin Liver Dis; 2010 Nov; 30(4):378-90. PubMed ID: 20960377
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The ins and outs of mitochondrial dysfunction in NASH.
    Fromenty B; Robin MA; Igoudjil A; Mansouri A; Pessayre D
    Diabetes Metab; 2004 Apr; 30(2):121-38. PubMed ID: 15223984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.